You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNafcillin
Accession NumberDB00607  (APRD01130, DB08269)
TypeSmall Molecule
GroupsApproved
Description

A semi-synthetic antibiotic related to penicillin. [PubChem]

Structure
Thumb
Synonyms
(2-Ethoxy-1-naphthalenyl)penicillin
(2-Ethoxy-1-naphthyl)penicillin
(2S,5R,6R)-6-{[(2-ethoxynaphthalen-1-yl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
6-(2-Ethoxy-1-naphthamido)penicillanic acid
Nafcilina
Nafcilline
Nafcillinum
Naphcillin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nafcillininjection, solution1 g/50mLintravenousBaxter Healthcare Corporation1989-10-31Not applicableUs
Nafcillininjection, solution2 g/100mLintravenousBaxter Healthcare Corporation1989-10-31Not applicableUs
Unipen Injection Pws 500mg/vialpowder for solution500 mgintramuscular; intravenousWyeth Ayerst Canada Inc.1994-12-311998-08-13Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nafcillininjection, powder, for solution10 g/100mLintravenousAPP Pharmaceuticals, LLC2011-04-27Not applicableUs
Nafcillinpowder, for solution1 g/1intramuscular; intravenousWG Critical Care, LLC2013-01-18Not applicableUs
Nafcillininjection2 g/1intramuscular; intravenousClaris Lifesciences, Inc.2012-02-01Not applicableUs
Nafcillininjection, powder, for solution2 g/1intramuscular; intravenousSandoz Inc1984-08-02Not applicableUs
Nafcillinpowder, for solution2 g/8mLintramuscular; intravenousAPP Pharmaceuticals, LLC2011-06-30Not applicableUs
Nafcillininjection1 g/1intramuscular; intravenousClaris Lifesciences, Inc.2012-02-01Not applicableUs
Nafcillininjection, powder, for solution1 g/1intramuscular; intravenousSandoz Inc1984-08-02Not applicableUs
Nafcillinpowder, for solution1 g/4mLintramuscular; intravenousAPP Pharmaceuticals, LLC2011-06-30Not applicableUs
Nafcillininjection, powder, for solution10 g/100mLintravenousSagent Pharmaceuticals2012-10-25Not applicableUs
Nafcillininjection, powder, for solution10 g/100mLintravenousAuro Medics Pharma Llc2012-12-26Not applicableUs
Nafcillininjection, powder, for solution2 g/8mLintramuscular; intravenousSagent Pharmaceuticals2012-10-25Not applicableUs
Nafcillininjection, powder, for solution1 g/4mLintramuscular; intravenousSagent Pharmaceuticals2012-10-25Not applicableUs
Nafcillininjection, powder, for solution10 g/100mLintravenousSandoz Inc1984-08-02Not applicableUs
Nafcillininjection, powder, for solution2 g/8mLintramuscular; intravenousAuro Medics Pharma Llc2012-12-26Not applicableUs
Nafcillininjection, powder, for solution2 g/1intramuscular; intravenousSandoz Inc1984-08-02Not applicableUs
Nafcillininjection, powder, for solution1 g/4mLintramuscular; intravenousAuro Medics Pharma Llc2012-12-26Not applicableUs
Nafcillininjection, powder, for solution10 g/100mLintravenousWG Critical Care, LLC2011-04-27Not applicableUs
Nafcillininjection, powder, for solution1 g/1intramuscular; intravenousSandoz Inc1984-08-02Not applicableUs
Nafcillinpowder, for solution2 g/1intramuscular; intravenousWG Critical Care, LLC2013-01-18Not applicableUs
Nafcillininjection, powder, for solution10 g/100mLintravenousSandoz Inc1984-08-02Not applicableUs
Nafcillin Sodiuminjection, powder, for solution1 g/4mLintramuscular; intravenousTeva Parenteral Medicines, Inc.2014-04-08Not applicableUs
Nafcillin Sodiuminjection, powder, for solution2 g/1intravenousSandoz Inc2005-09-23Not applicableUs
Nafcillin Sodiuminjection, powder, for solution1 g/1intravenousSandoz Inc2005-09-23Not applicableUs
Nafcillin Sodiuminjection, powder, for solution2 g/1intravenousSandoz Inc2005-09-23Not applicableUs
Nafcillin Sodiuminjection, powder, for solution1 g/1intravenousSandoz Inc2005-09-23Not applicableUs
Nafcillin Sodiuminjection, powder, for solution2 g/8mLintramuscular; intravenousTeva Parenteral Medicines, Inc.2014-04-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NallpenNot Available
UnipenNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Nafcillin Sodium
985-16-0
Thumb
  • InChI Key: AYAPZOUDXCDGIF-FRFVDRIFSA-M
  • Monoisotopic Mass: 436.106887157
  • Average Mass: 436.457
DBSALT000497
Categories
UNII4CNZ27M7RV
CAS number147-52-4
WeightAverage: 414.475
Monoisotopic: 414.124942514
Chemical FormulaC21H22N2O5S
InChI KeyInChIKey=GPXLMGHLHQJAGZ-JTDSTZFVSA-N
InChI
InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1
IUPAC Name
(2S,5R,6R)-6-(2-ethoxynaphthalene-1-amido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[[email protected]]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as penicillins. These are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting from the sulfur atom at position 1].
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassLactams
Sub ClassBeta lactams
Direct ParentPenicillins
Alternative Parents
Substituents
  • Penicillin
  • 1-naphthalenecarboxylic acid or derivatives
  • 1-naphthalenecarboxamide
  • N-acyl-alpha amino acid or derivatives
  • Naphthalene
  • Alpha-amino acid or derivatives
  • Benzamide
  • Benzoyl
  • Alkyl aryl ether
  • Benzenoid
  • Thiazolidine
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azetidine
  • Azacycle
  • Dialkylthioether
  • Hemithioaminal
  • Thioether
  • Monocarboxylic acid or derivatives
  • Ether
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs.
PharmacodynamicsNafcillin is a semisynthetic antibiotic substance derived from 6-amino-penicillanic acid. The drugs in this class are highly resistant to inactivation by staphylococcal penicillinase and are active against penicillinase-producing and non penicillinase-producing strains of Staphylococcus aureus. The penicillinase- resistant penicillins are active in vitro against a variety of other bacteria.
Mechanism of actionPenicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding89.9 ±1.5%
Metabolism

Hepatic metabolism accounts for less than 30% of the biotransformation of most penicillins.

Route of eliminationNafcillin is primarily eliminated by nonrenal routes, namely hepatic inactivation and excretion in the bile.
Half lifeThe serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.
ClearanceNot Available
ToxicitySerious toxicity is unlikely following large doses of nafcillin. Acute ingestion of large doses of nafcillin may cause nausea, vomiting, diarrhea and abdominal pain. Acute oliguric renal failure and hematuria may occur following large doses.
Affected organisms
  • Enteric bacteria and other eubacteria
  • Staphylococcus aureus
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5328
Blood Brain Barrier-0.9938
Caco-2 permeable-0.6248
P-glycoprotein substrateSubstrate0.708
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8807
Renal organic cation transporterNon-inhibitor0.923
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5
CYP450 1A2 substrateNon-inhibitor0.8164
CYP450 2C9 inhibitorNon-inhibitor0.7263
CYP450 2D6 inhibitorNon-inhibitor0.8869
CYP450 2C19 inhibitorNon-inhibitor0.8082
CYP450 3A4 inhibitorInhibitor0.5653
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7437
Ames testNon AMES toxic0.796
CarcinogenicityNon-carcinogens0.6679
BiodegradationNot ready biodegradable0.9972
Rat acute toxicity2.1208 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9994
hERG inhibition (predictor II)Non-inhibitor0.6449
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wyeth ayerst laboratories
  • Apothecon inc div bristol myers squibb
  • Marsam pharmaceuticals llc
  • Sandoz inc
  • Glaxosmithkline
  • Baxter healthcare corp
Packagers
Dosage forms
FormRouteStrength
Injectionintramuscular; intravenous1 g/1
Injectionintramuscular; intravenous2 g/1
Injection, powder, for solutionintramuscular; intravenous1 g/1
Injection, powder, for solutionintramuscular; intravenous2 g/1
Injection, powder, for solutionintravenous10 g/100mL
Injection, solutionintravenous1 g/50mL
Injection, solutionintravenous2 g/100mL
Powder, for solutionintramuscular; intravenous1 g/4mL
Powder, for solutionintramuscular; intravenous1 g/1
Powder, for solutionintramuscular; intravenous2 g/8mL
Powder, for solutionintramuscular; intravenous2 g/1
Injection, powder, for solutionintramuscular; intravenous1 g/4mL
Injection, powder, for solutionintramuscular; intravenous2 g/8mL
Injection, powder, for solutionintravenous1 g/1
Injection, powder, for solutionintravenous2 g/1
Powder for solutionintramuscular; intravenous500 mg
Prices
Unit descriptionCostUnit
Nafcillin 10 gm vial118.01USD vial
Nafcillin 2 gm vial24.08USD vial
Nafcillin 1 gm vial12.41USD vial
Nafcillin 1 gm/ 50 ml inj0.43USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySolubleNot Available
logP3.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0172 mg/mLALOGPS
logP3.21ALOGPS
logP2.29ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)3.31ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity108.14 m3·mol-1ChemAxon
Polarizability42.22 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesJ01CF06
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (44.1 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolNafcillin may increase the anticoagulant activities of Acenocoumarol.
AmikacinThe serum concentration of Amikacin can be decreased when it is combined with Nafcillin.
AmlodipineThe metabolism of Amlodipine can be increased when combined with Nafcillin.
AmrinoneThe metabolism of Amrinone can be increased when combined with Nafcillin.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Nafcillin.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Nafcillin.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Nafcillin.
BepridilThe metabolism of Bepridil can be increased when combined with Nafcillin.
BiotinThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Biotin.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Nafcillin.
ChlorotrianiseneThe metabolism of Chlorotrianisene can be increased when combined with Nafcillin.
ClarithromycinThe serum concentration of the active metabolites of Clarithromycin can be increased when Clarithromycin is used in combination with Nafcillin.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Nafcillin.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Nafcillin.
DemeclocyclineThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Demeclocycline.
DicoumarolNafcillin may decrease the anticoagulant activities of Dicoumarol.
DiltiazemThe metabolism of Diltiazem can be increased when combined with Nafcillin.
DoxycyclineThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Doxycycline.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Nafcillin.
FelodipineThe metabolism of Felodipine can be increased when combined with Nafcillin.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Nafcillin.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Nafcillin.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Nafcillin.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Nafcillin.
GabapentinThe metabolism of Gabapentin can be increased when combined with Nafcillin.
GentamicinThe serum concentration of Gentamicin can be decreased when it is combined with Nafcillin.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Nafcillin.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Nafcillin.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nafcillin resulting in a loss in efficacy.
IsradipineThe metabolism of Isradipine can be increased when combined with Nafcillin.
KanamycinThe serum concentration of Kanamycin can be decreased when it is combined with Nafcillin.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Nafcillin.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Nafcillin.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Nafcillin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nafcillin.
MinocyclineThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Minocycline.
Mycophenolate mofetilThe serum concentration of the active metabolites of Mycophenolate mofetil can be reduced when Mycophenolate mofetil is used in combination with Nafcillin resulting in a loss in efficacy.
Mycophenolic acidThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Nafcillin resulting in a loss in efficacy.
NeomycinThe serum concentration of Neomycin can be decreased when it is combined with Nafcillin.
NicardipineThe metabolism of Nicardipine can be increased when combined with Nafcillin.
NifedipineThe metabolism of Nifedipine can be increased when combined with Nafcillin.
NimodipineThe metabolism of Nimodipine can be increased when combined with Nafcillin.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Nafcillin.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Nafcillin.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Nafcillin.
OxytetracyclineThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Oxytetracycline.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Nafcillin.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Nafcillin.
Picosulfuric acidThe therapeutic efficacy of Sodium picosulfate can be decreased when used in combination with Nafcillin.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Nafcillin.
ProbenecidThe serum concentration of Nafcillin can be increased when it is combined with Probenecid.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Nafcillin.
RisedronateThe metabolism of Risedronate can be increased when combined with Nafcillin.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Nafcillin.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Nafcillin.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Nafcillin.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Nafcillin.
StreptomycinThe serum concentration of Streptomycin can be decreased when it is combined with Nafcillin.
TetracyclineThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Tetracycline.
TobramycinThe serum concentration of Tobramycin can be decreased when it is combined with Nafcillin.
VerapamilThe metabolism of Verapamil can be increased when combined with Nafcillin.
WarfarinNafcillin may increase the anticoagulant activities of Warfarin.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Transferase activity, transferring acyl groups
Specific Function:
Not Available
Gene Name:
pbp1b
Uniprot ID:
Q7CRA4
Molecular Weight:
89479.92 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Penicillin binding
Specific Function:
Not Available
Gene Name:
penA
Uniprot ID:
P0A3M6
Molecular Weight:
73872.305 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Transferase activity, transferring acyl groups
Specific Function:
Not Available
Gene Name:
pbp2a
Uniprot ID:
Q8DNB6
Molecular Weight:
80797.94 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type d-ala-d-ala carboxypeptidase activity
Specific Function:
Not Available
Gene Name:
pbp3
Uniprot ID:
Q75Y35
Molecular Weight:
45209.84 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]
Kind
Protein
Organism
Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
Pharmacological action
yes
Actions
inhibitor
General Function:
Penicillin binding
Specific Function:
Cell wall formation.
Gene Name:
pbpA
Uniprot ID:
Q8DR59
Molecular Weight:
79700.9 Da
References
  1. Williamson R, Hakenbeck R, Tomasz A: In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1980 Oct;18(4):629-37. [PubMed:7447421 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E, Bachmann K: A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos. 2008 Aug;36(8):1689-97. doi: 10.1124/dmd.108.020701. Epub 2008 May 27. [PubMed:18505790 ]
  2. Kim KY, Frey RJ, Epplen K, Foruhari F: Interaction between warfarin and nafcillin: case report and review of the literature. Pharmacotherapy. 2007 Oct;27(10):1467-70. [PubMed:17896903 ]
  3. Lang CC, Jamal SK, Mohamed Z, Mustafa MR, Mustafa AM, Lee TC: Evidence of an interaction between nifedipine and nafcillin in humans. Br J Clin Pharmacol. 2003 Jun;55(6):588-90. [PubMed:12814453 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. [PubMed:10411577 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:11